NCT00003993View on ClinicalTrials.gov

Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

July 31, 2008

Conditions
LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

aldesleukin

DRUG

bryostatin 1

Trial Locations (1)

21224-6825

National Institute on Aging - Baltimore, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

National Institute on Aging (NIA)

NIH

NCT00003993 - Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma | Biotech Hunter | Biotech Hunter